Evidence map›Paper›PMID 40334384›Full record

ArticleBreast (Edinburgh, Scotland)2025

Impact of routine FDG-PET/CT on locoregional treatment decisions in breast cancer patients receiving preoperative systemic therapy.

Jetske L B Gunster, A Marjolein Schrijver, Frederieke H van Duijnhoven, Marcel P M Stokkel, Corrie A M Marijnen, Astrid N Scholten

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast (Edinburgh, Scotland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jetske L B GunsterDepartment of Radiation Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands; Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: j.gunster@nki.nl.
A Marjolein SchrijverDepartment of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Frederieke H van DuijnhovenDepartment of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Marcel P M StokkelDepartment of Nuclear Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Corrie A M MarijnenDepartment of Radiation Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands; Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands.
Astrid N ScholtenDepartment of Radiation Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study evaluates the clinical impact of routine FDG-PET/CT on locoregional treatment in a large cohort of breast cancer patients scheduled for preoperative systemic therapy (PST).

methodsPatients scheduled for PST were identified from a retrospective database between 2011 and 2020 at our hospital. All patients underwent staging by FDG-PET/CT prior to PST. The rate of regional upstaging by FDG-PET/CT compared to initial locoregional staging was assessed, as well as its implications on surgical and radiotherapeutic management. Logistic regression analysis was used to evaluate the correlation between clinical characteristics and regional upstaging by FDG-PET/CT.

resultsAmong 1228 eligible patients, FDG-PET/CT detected additional regional lymph node involvement in 145 patients (12 %). This resulted in treatment modifications for 140 patients (11 %), including changes to the axillary surgical approach in 27 patients (2 %), and adjustments to the postoperative radiation therapy plans in 115 patients (9 %). The majority of these modifications occurred in patients initially staged as cN1(1-3) (92/140). Clinical T stage was significantly associated with regional upstaging by FDG-PET/CT.

conclusionFDG-PET/CT staging before PST frequently identifies additional regional lymph node involvement, significantly altering locoregional treatment strategies in the majority.

Indexed as

Breast NeoplasmsClinical Decision-MakingPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFemaleFluorodeoxyglucose F18HumansLymphatic MetastasisLymph NodesMiddle AgedNeoadjuvant TherapyNeoplasm StagingPreoperative CareRadiopharmaceuticalsFluorodeoxyglucose F18RadiopharmaceuticalsAxillary surgeryBreast cancerFDG-PET/CTPreoperative systemic therapyRegional radiation therapy

Identifiers

PMID40334384
PMCPMC12138562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.